| Bioactivity | Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4]. |
| Target | thrombin, factor Xa |
| Invitro | Ciraparantag is a small-molecule antidote for unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and certain direct oral anticoagulants (DOACs)[2].Ciraparantag is a small synthetic and cationic molecule that binds direct Xa inhibitors, direct thrombin inhibitors, and unfractionated and low molecular weight heparin (LMWH) through non-covalent hydrogen bonds and charge–charge interactions[3]. 0 --> Ciraparantag 相关抗体: |
| Name | Ciraparantag |
| CAS | 1438492-26-2 |
| Formula | C22H48N12O2 |
| Molar Mass | 512.70 |
| Appearance | 固体 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
| Reference | [1]. Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25. [2]. Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10. [3]. Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44. [4]. Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158. |
Ciraparantag
CAS: 1438492-26-2 F: C22H48N12O2 W: 512.70
Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants,
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.